Page 2 - Nasdaq Bcda News Today

BioCardia, Inc. (NASDAQ:BCDA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 13,000 shares, a decrease of 29.3% from the April 30th total of 18,400 shares. Currently, 0.1% of the shares of the company are sold short. […]

BioCardia, Inc. (NASDAQ:BCDA – Get Rating) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 27,400 shares, a drop of 26.9% from the March 15th total of 37,500 shares. Based on an average daily trading volume, of 26,600 shares, the days-to-cover ratio is […]

BioCardia (NASDAQ:BCDA – Get Rating)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 363.92% from the company’s current price. HC Wainwright also issued […]

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

Wall Street analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report $190,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for BioCardia’s earnings, with estimates ranging from $130,000.00 to $250,000.00. BioCardia reported sales of $70,000.00 during the same quarter last year, which indicates a positive year-over-year growth […]

BioCardia (NASDAQ:BCDA – Get Rating) had its price objective dropped by equities researchers at Maxim Group to $4.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s target price points to a potential upside of 151.57% from the stock’s previous close. Other analysts have also issued research reports about the […]

Equities analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will announce sales of $190,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for BioCardia’s earnings, with the lowest sales estimate coming in at $130,000.00 and the highest estimate coming in at $250,000.00. BioCardia posted sales of $50,000.00 during the […]

Wall Street analysts forecast that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report earnings per share of ($0.22) for the current quarter, according to Zacks. Two analysts have made estimates for BioCardia’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.33). BioCardia reported earnings per share of ($0.18) in the same quarter […]

Analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report earnings of ($0.22) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioCardia’s earnings, with estimates ranging from ($0.33) to ($0.16). BioCardia posted earnings per share of ($0.18) during the same quarter last year, which indicates a negative […]

BioCardia (NASDAQ:BCDA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company’s product candidate consists of CardiAMP(TM), […]